---
title: "China Resources Pharma Discloses Nine-Month Unaudited Results of Dong-E-E-Jiao"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302866006.md"
description: "China Resources Pharmaceutical Group disclosed unaudited nine-month results for subsidiary Dong-E-E-Jiao, reporting revenue of RMB4.94 billion and net profit of RMB1.33 billion as of September 2026. Despite modest growth, the company saw significant decreases in cash, total assets, and owner’s equity. The parent cautioned that these PRC GAAP figures are subject to audit adjustments and do not fully represent the group's financial position."
datetime: "2026-10-23T10:40:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302866006.md)
  - [en](https://longbridge.com/en/news/302866006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302866006.md)
generator: "portal-rs"
---

# China Resources Pharma Discloses Nine-Month Unaudited Results of Dong-E-E-Jiao

The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).

China Resources Pharmaceutical Group has disclosed the unaudited nine‑month financial results of its controlled subsidiary Dong-E-E-Jiao, highlighting the importance of the traditional Chinese medicine maker within the group’s portfolio. Dong-E-E-Jiao, in which the group effectively holds about 23.66%, remains consolidated as a subsidiary and provides investors with additional visibility into a key earnings contributor.

For the nine months ended 30 September 2026, Dong-E-E-Jiao reported modest revenue and profit growth, with revenue rising to RMB4.94 billion and net profit reaching RMB1.33 billion, compared with the same period a year earlier. However, the company recorded a significant net decrease in cash and cash equivalents and a reduction in total assets and owner’s equity, prompting the parent to caution shareholders that these unaudited PRC GAAP figures are subject to audit adjustments and should not be viewed as a full representation of the group’s financial position.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical conglomerate with a diversified portfolio spanning manufacturing, distribution and retail of medicines and health products. Through its control of Dong-E-E-Jiao Company Limited, a Shenzhen-listed producer of traditional Chinese medicine products, the group maintains a significant presence in China’s branded TCM and healthcare market.

**Average Trading Volume:** 8,017,719

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$29.25B

Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [000423.CN](https://longbridge.com/en/quote/000423.CN.md)

## Related News & Research

- [China Resources Pharmaceutical Unit Secures Approval for RMB 10 Billion Corporate Bond Issuance](https://longbridge.com/en/news/305661943.md)
- [China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion](https://longbridge.com/en/news/303715107.md)
- [China Resources Pharma Subsidiary Starts Pre-Bidding for Potential Share Issuance](https://longbridge.com/en/news/302114112.md)
- [China Resources Pharmaceutical Completes RMB 800 Million Medium-Term Note Issuance](https://longbridge.com/en/news/302856714.md)
- [CHINARES PHARMA  Subsidiary Enters Strategic Cooperation With SBP GROUP](https://longbridge.com/en/news/299397843.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**